Manufacturing
We have built global scale and world-class capabilities that leverage advanced technologies and an unwavering commitment to quality, to transform scientific breakthroughs into safe, efficacious, and affordable biosimilar therapies.
Early on in our journey, we chose to invest extensively in building internal capabilities, focusing on globally compliant manufacturing facilities that offer integrated capabilities across drug substance, drug product and devices. We have also developed expertise across various technology platforms, including microbial and mammalian systems, to produce insulins, monoclonal antibodies (mAbs), and conjugated recombinant proteins.
Biocon Biologics operates state-of-the-art manufacturing facilities in India, including one of the country’s largest mAbs manufacturing sites. Additionally, we run Asia’s largest integrated insulin facility in Johor, Malaysia. Our commercial reach has also been extended through collaborations with external manufacturing partners for the production of both drug substance and drug product. These facilities have been approved by international regulatory agencies, underscoring our global standards in biopharmaceutical manufacturing.
Global Manufacturing Network for Drug Product Facilities
Drivers of Change
End-to-End Manufacturing Capabilities
Biocon Biologics is a fully vertically integrated organization with the capability to manufacture drug substances, drug products and medical delivery devices. We run operations in India and Johor, Malaysia, for the production of insulins, conjugated peptides and monoclonal antibody (mAb) drug substances and products.
